Insider Selling: InspireMD (NYSE:NSPR) Insider Sells 22,778 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 22,778 shares of the company’s stock in a transaction dated Tuesday, May 19th. The shares were sold at an average price of $1.01, for a total value of $23,005.78. Following the transaction, the insider directly owned 1,053,882 shares in the company, valued at $1,064,420.82. This represents a 2.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

InspireMD Stock Performance

NYSE:NSPR traded up $0.03 during mid-day trading on Thursday, hitting $1.03. 160,140 shares of the company’s stock traded hands, compared to its average volume of 182,457. The company has a fifty day moving average of $1.40 and a 200 day moving average of $1.68. InspireMD, Inc. has a twelve month low of $0.97 and a twelve month high of $2.93. The company has a market capitalization of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82.

Institutional Trading of InspireMD

Hedge funds have recently modified their holdings of the stock. Ghisallo Capital Management LLC purchased a new stake in shares of InspireMD in the third quarter worth about $2,221,000. Aberdeen Group plc purchased a new stake in shares of InspireMD in the third quarter worth about $5,979,000. Rosalind Advisors Inc. boosted its stake in shares of InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after buying an additional 1,616,644 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of InspireMD in the fourth quarter worth about $31,000. Finally, XTX Topco Ltd purchased a new stake in shares of InspireMD in the fourth quarter worth about $30,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

Key Headlines Impacting InspireMD

Here are the key news stories impacting InspireMD this week:

• Neutral Sentiment: Shane Thomas Gleason disclosed multiple recent sales of InspireMD shares, including transactions on May 19, May 23, May 27, May 29, May 30, and earlier January/February dates. Each filing says the sales were made to cover tax withholding obligations related to the vesting of equity awards, which makes the activity look more routine than a strategic exit. Article Title
• Neutral Sentiment: A new “Stock Forecast & Price Target” page for InspireMD may be contributing to increased trading interest, but the item itself does not include a specific rating change, earnings update, or business development that would clearly drive the shares. Article Title

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Lake Street Capital set a $4.00 price objective on InspireMD in a report on Monday, May 4th. Loop Capital set a $5.00 price target on shares of InspireMD in a report on Tuesday, February 24th. Piper Sandler reissued an “overweight” rating and set a $3.00 price target (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Finally, Maxim Group assumed coverage on shares of InspireMD in a report on Monday, February 2nd. They issued a “buy” rating and a $6.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $4.50.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.